New York Medicaid Embraces TMS Therapy for Depressive Disorders
Expansion of TMS Therapy Coverage by New York Medicaid
MALVERN, Pa. — Neuronetics, Inc. (NASDAQ: STIM), a prominent medical technology company dedicated to enhancing the quality of life for those with neurohealth disorders, has exciting news. The state of New York has decided to expand Medicaid coverage to include Transcranial Magnetic Stimulation (TMS) therapy for adults suffering from major depressive disorder (MDD). This groundbreaking coverage will commence on October 1 for fee-for-service Medicaid recipients and on November 1 for participants in Medicaid Managed Care Plans.
Significance of the Coverage Decision
Keith J. Sullivan, the President and CEO of Neuronetics, expressed his gratitude regarding this pivotal development. He stated, "This decision by New York State Medicaid reflects the growing recognition of TMS as an evidence-based, life-changing treatment for patients with depression." Sullivan emphasized the company's dedication to collaborating with healthcare providers and policymakers to make TMS more accessible nationwide.
The Impact of MDD in the U.S.
Major depressive disorder is a significant health concern in the United States, affecting around 21 million adults. Among these individuals, approximately 6.4 million cannot tolerate or find relief from standard antidepressants. This fact highlights the critical need for alternative treatments like NeuroStar Advanced Therapy, which offers a non-invasive option aimed at stimulating the brain's neurons responsible for mood regulation.
Understanding NeuroStar Advanced Therapy
NeuroStar Advanced Therapy utilizes targeted magnetic pulses to address treatment-resistant depression. The results from the NeuroStar Outcomes Database are promising, revealing an impressive 83% response rate and a 62% remission rate among patients battling MDD. Such effectiveness underscores the importance of TMS as a reliable and effective treatment method.
Neuronetics: A Leader in Neurohealth Solutions
As the only TMS provider with a dedicated health policy team, Neuronetics works tirelessly to advocate for health policy improvements that benefit both patients and providers. The company is not just focused on selling the NeuroStar Advanced Therapy system, but also on expanding treatment options for mental health conditions. Through their various treatment centers across the United States, they have administered over 7.6 million sessions of TMS therapy.
Comprehensive Mental Health Solutions
Alongside NeuroStar Advanced Therapy, Neuronetics also collaborates with Greenbrook TMS Inc. to enhance access to treatment for MDD. Greenbrook centers have successfully delivered more than 1.8 million treatments, helping over 55,000 patients reclaim their mental well-being. It’s also noteworthy that they offer SPRAVATO (esketamine) Nasal Spray, which is used in conjunction with therapy to treat treatment-resistant depression effectively.
FDA Approval and Safety Information
The NeuroStar Advanced Therapy System has received clearance from the U.S. Food and Drug Administration. It is approved for use not only in adults with major depressive disorder but also as an adjunct treatment for adolescents aged 15-21. Neuronetics continues to prioritize patient safety and insists on transparency regarding treatment protocols.
Frequently Asked Questions
What is TMS therapy?
TMS therapy is a non-invasive treatment that utilizes magnetic pulses to stimulate specific parts of the brain, aimed at improving symptoms of major depressive disorder.
Who is Neuronetics?
Neuronetics, Inc. is a leader in the development of innovative medical technologies aimed at enhancing the treatment of neurohealth conditions.
How will the Medicaid coverage impact patients?
The expanded Medicaid coverage will allow thousands of additional patients to access TMS therapy, significantly broadening treatment options for those with depression.
What are the outcomes of NeuroStar therapy?
The NeuroStar therapy has shown an 83% response rate and a 62% remission rate in patients suffering from major depressive disorder.
Where can I find more information about NeuroStar Therapy?
For more information, patients and providers can visit the NeuroStar Therapy website at NeuroStar.com.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
